Annual CFO
N/A
December 31, 2024
Summary
- PRLD annual cash flow from operations is not available.
Performance
PRLD Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
Quarterly CFO
N/A
December 31, 2024
Summary
- PRLD quarterly cash flow from operations is not available.
Performance
PRLD Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
TTM CFO
N/A
December 31, 2024
Summary
- PRLD TTM cash flow from operations is not available.
Performance
PRLD TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
Cash From Operations Formula
CFO = Net Income + Non Cash Expenses + Changes In Working Capital
PRLD Cash From Operations Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | - | - | - |
| 3 y3 years | - | - | - |
| 5 y5 years | - | - | - |
PRLD Cash From Operations Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | ||||||
| 5 y | 5-year | ||||||
| alltime | all time |
Prelude Therapeutics Incorporated Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$27.30 M(+18.4%) | -$105.72 M(+1.5%) |
| Jun 2024 | - | -$23.06 M(-27.5%) | -$104.11 M(-4.2%) |
| Mar 2024 | - | -$31.79 M(+34.8%) | -$108.72 M(+1.5%) |
| Dec 2023 | -$107.06 M(+27.9%) | -$23.58 M(-8.2%) | -$107.06 M(+0.6%) |
| Sep 2023 | - | -$25.68 M(-7.2%) | -$106.41 M(+5.2%) |
| Jun 2023 | - | -$27.67 M(-8.2%) | -$101.17 M(+10.0%) |
| Mar 2023 | - | -$30.13 M(+31.4%) | -$91.97 M(+9.8%) |
| Dec 2022 | -$83.73 M | -$22.93 M(+12.2%) | -$83.73 M(-3.2%) |
| Sep 2022 | - | -$20.44 M(+10.7%) | -$86.50 M(-1.5%) |
| Jun 2022 | - | -$18.47 M(-15.7%) | -$87.84 M(-1.6%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2022 | - | -$21.89 M(-14.8%) | -$89.28 M(+6.9%) |
| Dec 2021 | -$83.53 M(+80.9%) | -$25.70 M(+18.0%) | -$83.53 M(+14.9%) |
| Sep 2021 | - | -$21.77 M(+9.4%) | -$72.68 M(+14.6%) |
| Jun 2021 | - | -$19.91 M(+23.3%) | -$63.41 M(+21.0%) |
| Mar 2021 | - | -$16.14 M(+8.7%) | -$52.40 M(+13.5%) |
| Dec 2020 | -$46.18 M(+79.9%) | -$14.85 M(+18.7%) | -$46.18 M(+47.4%) |
| Sep 2020 | - | -$12.51 M(+40.5%) | -$31.33 M(+66.4%) |
| Jun 2020 | - | -$8.90 M(-10.3%) | -$18.82 M(+89.7%) |
| Mar 2020 | - | -$9.92 M | -$9.92 M |
| Dec 2019 | -$25.66 M(+98.1%) | - | - |
| Dec 2018 | -$12.95 M | - | - |
FAQ
- What is the all time high annual CFO for Prelude Therapeutics Incorporated?
- What is the all time high quarterly CFO for Prelude Therapeutics Incorporated?
- What is the all time high TTM CFO for Prelude Therapeutics Incorporated?
What is the all time high annual CFO for Prelude Therapeutics Incorporated?
Prelude Therapeutics Incorporated all-time high annual cash flow from operations is -$12.95 M
What is the all time high quarterly CFO for Prelude Therapeutics Incorporated?
Prelude Therapeutics Incorporated all-time high quarterly cash flow from operations is -$8.90 M
What is the all time high TTM CFO for Prelude Therapeutics Incorporated?
Prelude Therapeutics Incorporated all-time high TTM cash flow from operations is -$9.92 M